Current and Future State of Cardiovascular Disease and Type 2 Diabetes
Prediabetes and Cardiovascular Risks: A Primary Call To Action | Patient-Centered Management of Diabetes and Prevention of Cardiovascular Disease | Managing Macrovascular Complications in Patients with Diabetes
Expires: 11/30/2021 (subject to change)
- CE for this activity will not be available after this date.
This is a multi-module CE activity that addresses the optimal management of type 2 diabetes in the context of cardiovascular disease. In the first case activity, faculty will discuss the pathophysiology and complication of prediabetes and through a case scenario identify risk factors, screening and diagnostic criteria. In the second case activity, faculty will discuss behavioral interventions to mitigate CVD and diabetes-related kidney disease risk reduction in T2DM as well as strategies to optimize glycemic goals using CVOT drug classes. Additionally, they will address using a team approach to encourage patient-centered diabetes self-management skills, education, and support. In the third case activity, faculty will discuss the impact of hypoglycemia in patients with advanced coronary artery disease and offer techniques to mitigate the risk of hypoglycemia. They will review cardiovascular outcome trial (CVOT) results and their application for pharmacologic interventions for patients with advanced diabetes related complications.
Case Activity 1:
Case Activity 2:
- Discuss the epidemiology of prediabetes and diabetes.
- Review risk factors, screening tools and diagnostic criteria for prediabetes and diabetes.
- Describe the pathophysiology and complications of prediabetes.
- Analyze the relationship between prediabetes and cardiovascular disease.
- Develop and implement screening strategies for a patient presenting with prediabetes.
- Formulate an evidence-based treatment plan for patients with prediabetes including lifestyle and pharmacologic interventions.
Case Activity 3:
- Discuss prevalence and associations of diabetes, CVD, and DKD.
- Recognize diabetes as a CVD equivalent and accelerator.
- Review behavioral interventions for mitigating CVD and DKD risk in T2DM.
- Distinguish major drug classes and outcomes from CVOTs related to impacts on glycemic control, CVD and DKD risk reduction in T2DM.
- Develop clinical strategies using CVOT drug classes to optimize glycemic goals and reduce CVD and DKD risk for patients with T2DM.
- Implement a team approach to diabetes care encouraging patient-centered diabetes self-management skills, education and support (DSMES).
- Review major risk factors for coronary artery disease, diabetic kidney disease (DKD) and heart failure in patients with type 2 diabetes mellitus (T2DM).
- Summarize the associations of T2DM, cardiovascular (CVD) and (DKD) and implications to the progression of cardiorenal syndrome (CRS) and cardiovascular mortality.
- Apply cardiovascular outcome trial (CVOT) results to provide guidance on appropriate pharmacologic interventions for patients with advanced diabetes related complications.
- Analyze the impact of hypoglycemia in patients with advanced coronary artery disease and discuss techniques for mitigating risk of hypoglycemia.
- Employ tools and techniques to improve adherence and long-term chronic disease outcomes.
Jonathan Purnell, MD (Chair)
Angela Thompson, DNP, FNP-C, BC-ADM, CDCES, FAANP (Faculty)
Jeff Unger, MD, FAAFP, FACE (Faculty)
Jonathan Weber, MA, PA-C (Faculty)
This program was planned in accordance with AANP CE Standards and Policies.
- Jonathan Purnell- Consultant, Advisory board - Novo Nordisk
- Angela Thompson Consultant, Focus group - Novo Nordisk
- Jeff Unger - Consultant, Speaker, Advisory Board, Primary Investigator - Novo Nordisk; Consultant, Advisory Board, Speaker - Abbott Diabetes; Speaker - Allergan
- Jonathan Weber has no relevant relationships to disclose.
All Planners have no relevant financial relationships to disclose.
This project is supported by an independent medical education grant from Boehringer Ingelheim Pharmaceutical, Inc, Lilly USA, LLC and Novo Nordisk.
Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
This activity was developed through a partnership between the Endocrine Society, American Academy of Family Physicians (AAFP), and the American Academy of PAs (AAPA).
CE Credit Instructions
Note: This multi-module series allows learners to select the modules that they want to complete in any order that they want to complete them in. CE/Rx credit and a completion certificate will be awarded for EACH module that is completed.
- Read this activity description, including objectives and disclosures.
- Complete the Pretest associated to the activity.
- Complete the educational content:
- Video Presentations: Click the Play button to watch the activity presentation. Full participation credit for the activity will be received once the entire video has been watched.
- Click on the Additional Resources button to review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
- After completing all content, click on the blue Next Steps button:
- Complete the post-test and pass with a score of at least 70% (4 attempts allowed).
- Submit the evaluation to receive full AANP CE/Rx credit.
For questions or more information concerning this online CE opportunity contact the AANP CE Center Manager at CECenter@aanp.org.